AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27283365 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral bovine colostrum
Number of subjects: 86
Study 26088042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration group (increased water intake by 1 to 1.5 l/day)
Number of subjects: 29
Study 26088042 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual fluid intake)
Number of subjects: 29
Study 26088042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration group (increased water intake)
Number of subjects: 29
Study 24075206 — intervention group
Group type: EXPERIMENTAL
Intervention: Less Invasive Surfactant Administration (LISA)
Number of subjects: 1000
Study 24075206 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with intratracheal bolus administration of surfactant
Number of subjects: 1000
Study 21682970 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid 100 mg daily for 14 days
Number of subjects: 48
Study 21682970 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid 200 mg daily for 14 days
Number of subjects: 48
Study 21682970 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid 300 mg daily for 14 days
Number of subjects: 48
Study 21682970 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid 400 mg daily for 14 days
Number of subjects: 48
Study 21682970 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosages of Delamanid combined
Number of subjects: 48
Study 19183825 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (drug therapy alone or combined with behavioral therapy) for 10 weeks
Number of subjects: 307
Study 19183825 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after stopping therapy for 6 months
Number of subjects: 307
Study 16918122 — intervention group
Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 50
Study 16918122 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 50
Study 15572491 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (200-mcg tablet)
Number of subjects: 848
Study 15572491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 848
Study 11489026 — intervention group
Group type: EXPERIMENTAL
Intervention: Handholding during surgery
Number of subjects: 62
Study 11489026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no handholding)
Number of subjects: 62
Study 11489026 — intervention group
Group type: EXPERIMENTAL
Intervention: Handholding group
Number of subjects: 62
Study 11489026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 9859573 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (Abciximab, tirofiban, lamifiban, integrelin)
Number of subjects: 0
Study 9859573 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study 8089244 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) rinses, 15 ml, 2 times daily for 30 days starting 2 days after extraction
Number of subjects: 40
Study 8089244 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution rinses for 30 days starting 2 days after extraction
Number of subjects: 40
Study 8089244 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) rinses
Number of subjects: 40
Study 2700774 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (37.5 mg/day)
Number of subjects: 265
Study 2700774 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 mg/day)
Number of subjects: 265
Study 2700774 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine and Amitriptyline
Number of subjects: 265
Study 1105484 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 1000
Study 31919695 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Treatment (FBT)
Number of subjects: 150
Study 31919695 — intervention group
Group type: COMPARATOR
Intervention: Parent-Based Treatment (PBT)
Number of subjects: 150
Study 31919695 — intervention group
Group type: COMPARATOR
Intervention: Hispanic families
Number of subjects: 150
Study 31380506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 137
Study 31380506 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 137
Study 28205255 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral therapy (ART)
Number of subjects: 1472
Study 28205255 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant nevirapine (NVP)
Number of subjects: 1472
Study 28205255 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1472
Study 26153888 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive Remediation Therapy (NCRT)
Number of subjects: 0
Study 26153888 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22683294 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Activation Intervention (PAI)
Number of subjects: 0
Study 22683294 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid video (DA)
Number of subjects: 0
Study 22683294 — intervention group
Group type: EXPERIMENTAL
Intervention: DA + PAI
Number of subjects: 0
Study 22683294 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20129883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic handpiece with precurved files
Number of subjects: 35
Study 20129883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel‐titanium rotary files
Number of subjects: 35
Study 20129883 — intervention group
Group type: COMPARATOR
Intervention: Sonic handpiece with straight files (control)
Number of subjects: 35
Study 19097507 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (n = 33)
Number of subjects: 65
Study 19097507 — intervention group
Group type: COMPARATOR
Intervention: Medication group (n = 32)
Number of subjects: 65
Study 15998785 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dairy, increase calcium intake to approximately 1000-1100 mg/d
Number of subjects: 154
Study 15998785 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy, increase calcium intake to approximately 1200-1300 mg/d
Number of subjects: 154
Study 15998785 — intervention group
Group type: COMPARATOR
Intervention: Control, continuous established (<800 mg/d) dietary calcium intake
Number of subjects: 154
Study 12122230 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 57
Study 12122230 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 57
Study 12122230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 10747211 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 40
Study 10747211 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 40
Study 10747211 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine concentration increase
Number of subjects: 40
Study 10747211 — intervention group
Group type: EXPERIMENTAL
Intervention: Core temperature decrease
Number of subjects: 40
Study 10747211 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative myocardial ischaemia
Number of subjects: 40
Study 8537987 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 0
Study 2073222 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 49
Study 2073222 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 49
Study 2073222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 49
Study 7141392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at 7 to 8 mg/kg/day and 14 to 15 mg/kg/day
Number of subjects: 223
Study 7141392 — intervention group
Group type: COMPARATOR
Intervention: Chenodeoxycholic acid (CDCA) at 7 to 8 mg/kg/day and 14 to 15 mg/kg/day
Number of subjects: 223
Study 31446153 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day)
Number of subjects: 40
Study 31446153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29064743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg QD + Metformin 1000 mg BID (COMBO)
Number of subjects: 24
Study 29064743 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1000 mg BID (MET)
Number of subjects: 24
Study 25495769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (PUS) therapy
Number of subjects: 60
Study 25495769 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin phonophoresis (EP) therapy
Number of subjects: 60
Study 23334901 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation with standard protocol for defibrillation testing
Number of subjects: 41
Study 22778571 — intervention group
Group type: EXPERIMENTAL
Intervention: Introducer curving technique (Group T)
Number of subjects: 108
Study 22778571 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 108
Study 19772445 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin
Number of subjects: 500
Study 19772445 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 500
Study 19772445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 500
Study 17136563 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate cream once daily for 4 weeks
Number of subjects: 16
Study 17136563 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular alefacept 15 mg for 12 weeks
Number of subjects: 16
Study 16863969 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof Natural intraocular lens (IOL) in one eye
Number of subjects: 46
Study 16863969 — intervention group
Group type: COMPARATOR
Intervention: Conventional AcrySof IOL in the fellow eye
Number of subjects: 46
Study 12590402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day)
Number of subjects: 24
Study 12590402 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg/day)
Number of subjects: 24
Study 12590402 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mirtazapine and amitriptyline
Number of subjects: 24
Study 12590402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10755338 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings (Comfeel and Varihesive)
Number of subjects: 38
Study 10755338 — intervention group
Group type: COMPARATOR
Intervention: Conventional gauze dressing (control)
Number of subjects: 38
Study 8665199 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy plus lateral internal sphincterotomy (group 2)
Number of subjects: 33
Study 8665199 — intervention group
Group type: COMPARATOR
Intervention: Haemorrhoidectomy alone (control, group 1)
Number of subjects: 33
Study 1503165 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program plus nicotine gum
Number of subjects: 417
Study 1503165 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program plus behavioral weight control
Number of subjects: 417
Study 1503165 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program plus both nicotine gum and behavioral weight control
Number of subjects: 417
Study 1503165 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation program
Number of subjects: 417
Study 6384455 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard WHO oral glucose-electrolyte solution containing 90 mmol of sodium per liter (Group A: 22 infants)
Number of subjects: 65
Study 6384455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose-electrolyte solution containing 60 mmol of sodium per liter (Group B: 22 infants)
Number of subjects: 65
Study 6384455 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous therapy (Group C: 21 infants)
Number of subjects: 65
Study 31868916 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-Needle Aspiration (FNA) for hepatic sampling
Number of subjects: 31
Study 31868916 — intervention group
Group type: COMPARATOR
Intervention: Core Needle Biopsy (CNB)
Number of subjects: 31
Study 28116988 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuomotor feedback training (VFT)
Number of subjects: 20
Study 28116988 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 20
Study 29059263 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily financial incentives of $60 monthly with $2 deducted for each day of nonadherence to glucose monitoring goals (4 or more checks per day, with 1 or more levels within the goal range of 70-180 mg/dL) during a 3-month intervention period.
Number of subjects: 90
Study 29059263 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives).
Number of subjects: 90
Study 29059263 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily financial incentives of $60 monthly with $2 deducted for each day of nonadherence to glucose monitoring goals during a 3-month intervention period.
Number of subjects: 90
Study 25432449 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:yttrium‐aluminum‐garnet laser
Number of subjects: 15
Study 25432449 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotary instruments
Number of subjects: 15
Study 23333553 — intervention group
Group type: EXPERIMENTAL
Intervention: Four isocaloric eating episodes at T0, T60, T120, and T180 min (F4)
Number of subjects: 20
Study 23333553 — intervention group
Group type: COMPARATOR
Intervention: One eating episode at T0 (F1)
Number of subjects: 20
Study 21275630 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-B4-blocked ricin (anti-B4-bR)
Number of subjects: 157
Study 21275630 — intervention group
Group type: COMPARATOR
Intervention: observation
Number of subjects: 157
Study 19650746 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0
Study 19650746 — intervention group
Group type: EXPERIMENTAL
Intervention: New inhibitors of the proton pump (potassium-competitive acid blockers)
Number of subjects: 0
Study 19650746 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux inhibitors (GABA(B) receptor agonists and mGluR5 antagonists)
Number of subjects: 0
Study 19650746 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral analgesics and growth factors
Number of subjects: 0
Study 16730271 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 2500
Study 16730271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 14759379 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus niacin (mean daily dose 13 mg and 2.4 g, respectively)
Number of subjects: 160
Study 14759379 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus niacin
Number of subjects: 160
Study 14759379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 11565960 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic stuttering
Number of subjects: 8
Study 11565960 — intervention group
Group type: COMPARATOR
Intervention: Developmental stuttering
Number of subjects: 8
Study 9414969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose (34 g per day)
Number of subjects: 46
Study 9414969 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (34 g per day)
Number of subjects: 46
Study 8488995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rüsch 'red rubber' tube (low‐volume, high‐pressure cuff)
Number of subjects: 150
Study 8488995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rüsch 'Super Safety Clear' tube (high‐volume, low‐pressure cuff)
Number of subjects: 150
Study 8488995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mallinckrodt 'lo‐pro' tube (high‐volume, low‐pressure cuff)
Number of subjects: 150
Study 8488995 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 3716756 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg)
Number of subjects: 120
Study 3716756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31705740 — intervention group
Group type: EXPERIMENTAL
Intervention: real continuous theta‐burst stimulation (cTBS)
Number of subjects: 16
Study 31705740 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 16
Study 29791971 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium histolyticum (CCH) treatment
Number of subjects: 135
Study 28628502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 26564457 — intervention group
Group type: EXPERIMENTAL
Intervention: Meibomian gland tube massage in addition to corticosteroid eye ointment and artificial tears
Number of subjects: 0
Study 26564457 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid eye ointment and artificial tears
Number of subjects: 0
Study 23700337 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Exposure (RE) group; 2 kJ/g; n = 32
Number of subjects: 95
Study 23700337 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavor-Flavor Learning (FFL) group; 2 kJ/g; n = 32
Number of subjects: 95
Study 23700337 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavor-Nutrient Learning (FNL) group; 6 kJ/g; n = 31
Number of subjects: 95
Study 21684012 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 32
Study 21684012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18285718 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES) before SEMS placement
Number of subjects: 74
Study 18285718 — intervention group
Group type: COMPARATOR
Intervention: No Endoscopic sphincterotomy (ES) before SEMS placement
Number of subjects: 74
Study 16777545 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination offered annually to all people after age 50
Number of subjects: 4000000
Study 16777545 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination offered to persons aged 65 and older
Number of subjects: 4000000
Study 16777545 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination for persons aged 65 and older
Number of subjects: 4000000
Study 16777545 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination for persons aged 50 to 64
Number of subjects: 4000000
Study 16777545 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination for persons aged 50 to 64 (excluding costs of patient time and travel)
Number of subjects: 4000000
Study 14581723 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 25
Study 14581723 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 25
Study 14581723 — intervention group
Group type: COMPARATOR
Intervention: Both gentamicin and amikacin
Number of subjects: 25
Study 14624189 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/d)
Number of subjects: 583
Study 14624189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study 10641042 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated peppermint-caraway oil combination (90 mg peppermint oil and 50 mg caraway oil)
Number of subjects: 6
Study 10641042 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-enteric-coated peppermint-caraway oil combination (90 mg peppermint oil and 50 mg caraway oil)
Number of subjects: 6
Study 8878595 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2,000 mg of clarithromycin (CLARI) plus 200 mg of minocycline (MINO), with or without 800 mg of ofloxacin (OFLO)
Number of subjects: 50
Study 8878595 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 600 mg of rifampin
Number of subjects: 50
Study 8878595 — intervention group
Group type: EXPERIMENTAL
Intervention: Month-long regimen with dapsone (DDS) and clofazimine (CLO) components of the standard MDT
Number of subjects: 50
Study 8878595 — intervention group
Group type: EXPERIMENTAL
Intervention: Month-long standard regimen of multidrug therapy (MDT) for multibacillary leprosy
Number of subjects: 50
Study 8878595 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of CLARI-MINO, with or without OFLO
Number of subjects: 50
Study 8878595 — intervention group
Group type: EXPERIMENTAL
Intervention: CLARI-MINO, with or without OFLO
Number of subjects: 50
Study 1906152 — intervention group
Group type: EXPERIMENTAL
Intervention: hMGs following midluteal pre‐treatment with leuprolide
Number of subjects: 97
Study 1906152 — intervention group
Group type: COMPARATOR
Intervention: hMGs alone
Number of subjects: 97
Study 6506175 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 mg elemental iron
Number of subjects: 0
Study 6506175 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 mg elemental iron plus 75 mg vitamin C
Number of subjects: 0
Study 6506175 — intervention group
Group type: COMPARATOR
Intervention: 100 mg vitamin C daily
Number of subjects: 0
Study 31876673 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 55
Study 31876673 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 29475874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) values 80-89 mm Hg
Number of subjects: 1703
Study 29475874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) values 70-79 mm Hg
Number of subjects: 1703
Study 29475874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) values 60-69 mm Hg
Number of subjects: 1703
Study 29475874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) values < 60 mm Hg
Number of subjects: 1703
Study 26708320 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 10 mg/day
Number of subjects: 426
Study 26708320 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg/day
Number of subjects: 426
Study 26708320 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50 mg/day
Number of subjects: 426
Study 26708320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 24528999 — intervention group
Group type: EXPERIMENTAL
Intervention: p,p'-DDE
Number of subjects: 1016
Study 24528999 — intervention group
Group type: EXPERIMENTAL
Intervention: PCB 105 and 118
Number of subjects: 1016